ArticleThoracic research and practice2026
Emrelis: A New Approach in Treating MET-high Locally Advanced or Metastatic Non-squamous NSCLC; A Mini Review.
Article in Thoracic research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers; however, a subset of patients experiences disease progression associated with alterations in the Mesenchymal-Epithelial Transition Factor (c-MET) pathway. These include MET exon 14-skipping mutations, which promote tumor growth, metastasis, and resistance to epidermal growth factor receptor (EGFR)-targeted therapies. Telisotuzumab vedotin (TV-t, Emrelis), a novel first-in-class c-MET inhibitor, is under investigation as a targeted therapy for c-MET-high NSCLC. This article highlights the therapeutic potential of TV-t as a targeted therapy for advanced NSCLC patients with limited post-treatment options. A targeted literature review was conducted using PubMed and ClinicalTrials.gov (2018 and 2025) with terms including "Telisotuzumab Vedotin," "c-MET," "c-MET-high," "c-MET overexpression," "MET exon 14," and "NSCLC." Both clinical and preclinical studies of the efficacy, safety, and pharmacological properties of TV-t were included. Also, those studies reported clinical findings relevant to TV-t in c-MET-altered NSCLC. In the pivotal LUMINOSITY phase II trial, TV-t showed a 28.6% overall response rate (ORR) in EGFR-wildtype, c-MET-overexpressing NSCLC, with 34.6% ORR in c-MET-high patients. Median duration of response was 9.0 months, overall survival 14.5 months, and progression-free survival (PFS) 5.7 months for the c-MET-high subgroup. In phase Ib studies, TV-t combined with osimertinib achieved a 50% ORR and 7.4-month PFS, while TV-t with nivolumab, the median PFS was 7.2 months, but ORR was low (7.4%). Common grade 3 or higher toxicities occurred in 27.9% of patients and included neuropathy, anemia, and pulmonary embolism, with no hepatotoxicity. Remarkable cardiac safety was observed. TV-t demonstrated promising efficacy and tolerability in patients, highlighting its clinical potential. However, further studies are needed to confirm its survival advantage, the durability of response, and safety profile, and to establish its long-term value and support its integration into routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.